The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes.

No abstract

Background Understanding the risk factors responsible for the increased infection among HCWs can mitigate the transmission of COVID-19 among HCWs and patients alike. The aim of this study is to evaluate factors associated with SARS-CoV-2 infection among healthcare Workers. Methods Healthcare workers and hospital administrators were asked to participate in this cross-sectional survey study that was conducted in Jaber Al Ahmad Hospital (JAH) between August to October 2020. Participants were invited to undergo SARS-CoV-2-specific antibody testing and to complete a questionnaire targeted to factors that may be associated with acquisition of SARS-CoV-2. Descriptive analysis and multivariate logistic regression were done. Results 847 healthcare workers participated in the study and 20.5 % of them had previous SARS-CoV-2 infection. The average age of participants was 35.7 years (SD = 7.9); 52.4% were female, and 55.8% were doctors. Multivariate analysis showed that working as a nurse (adjusted OR 1.77, 95% CI = 1.15, 2.71), and wearing gloves (adjusted OR 2.93, 95% CI = 1.19, 7.22) were significantly associated with an increased likelihood of contracting SARS-CoV-2 infection while controlling for other factors. Most personal protective equipment (PPE) were reported to be available always or most of the time, with the least available PPE item being coveralls (74.4%). Conclusions After adjusting for confounding factors, being a nurse and prolonged glove use were associated with increased likelihood of SARS-CoV-2 infection. Prospective cohort studies are required to further elucidate the reasons for our findings in order to minimize the transmission of infection among healthcare workers.

Case identification, isolation and contact tracing are fundamental strategies used to control the spread of Coronavirus Disease 2019 (COVID-19). This has led to widespread testing that resulted in the interruption of the supply chain for testing materials around the world. A prospective study was conducted to compare cheap and easily sourced 3-dimensionally printed polylactic acid and polyester nasopharyngeal swabs to commercially manufactured swabs, in detecting severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). During the study period, 287 laboratory-confirmed hospitalized COVID-19 patients, at multiple stages of their illness, were enrolled. The median age for the study population was 47.6 years (IQR: 34.4-56.6 years) and two-thirds (67.6%) of the subjects were male. The median duration of hospitalization, at the time of sampling, was 13 days (IQR 10-16 days). Overall concordance between the prototype and control swabs was 80.8% (Cohen's kappa coefficient = 0.61). Most discrepant results were due to prototype-positive control-negative results. When considering all positive results to be true positives, the prototype swab had a higher sensitivity (90.6% vs 80.8%, 95%CI 85.7-94.0% and 74.7-85.7%, respectively, p < 0.015). The cost to produce the prototype swab was estimated to be 0.05 USD per swab. Polylactic acid 3D-printed polyester-tipped swabs were shown to be effective for nasopharyngeal sample collection. We believe that this design can easily be adopted in countries where commercial swabs are not readily available and can play a vital role in public health efforts for disease control in low-income countries.